title: Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients.
abstract: Many factors are involved in the pathogenesis of Alzheimer's disease (AD), and inflammatory-immunologic activation seems to play a major role. One strategy for treatment of AD has been to use acetylcholinesterase (AChE) inhibitors to increase the levels of acetylcholine and enhancing cholinergic activity in the affected regions of the brain. Cholinergic compounds modulate the immune system, therefore secretion, by peripheral blood mononuclear cells (PBMC), of cytokines was investigated in age-matched controls and in AD patients. Cytokines released by PBMC from AD patients enrolled as pre-treatment patients (T0) and as post-treatment with AchEI (T1), were detected by ELISA assay. The result showed an increase in oncostatin M, interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) secretion in AD patients compared to healthy controls, and a decrease of cytokine levels in each AD patients treated for 1 month with an acetylcholinesterase inhibitor (AchEI). In conclusion, the results of this study show that the complex pathology in AD may be reflected in a pattern of altered cytokine secretion from PBMC.
authors.affiliation: Department of Oncology and Neuroscience, Unit of Immunology, University G. D'Annunzio, Via dei Vestini, 31, 66123 Chieti, Italy. mreale@unich.it
authors.forename: Marcella
authors.initials: M
authors.lastname: Reale
authors.forename: Carla
authors.initials: C
authors.lastname: Iarlori
authors.forename: Francesco
authors.initials: F
authors.lastname: Gambi
authors.forename: Isabella
authors.initials: I
authors.lastname: Lucci
authors.forename: Mirella
authors.initials: M
authors.lastname: Salvatore
authors.forename: Domenico
authors.initials: D
authors.lastname: Gambi
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology*; D016022:Case-Control Studies; D002478:Cells, Cultured; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism*; D000077265:Donepezil; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D053683:Oncostatin M; D010455:Peptides / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use*
chemical_list: D002800:Cholinesterase Inhibitors; D016207:Cytokines; D007189:Indans; D007375:Interleukin-1; D015850:Interleukin-6; C508351:OSM protein, human; D010455:Peptides; D010880:Piperidines; D053683:Oncostatin M; D000077265:Donepezil